Ketamine + Dexmedetomidine

The ketamine and dexmedetomidine combination represents one of the most widely used injectable anesthetic protocols in small mammal veterinary medicine, providing reliable chemical immobilization with the significant advantage of partial reversibility. Ketamine is a dissociative anesthetic that produces a cataleptic state through antagonism of N-methyl-D-aspartate receptors in the central nervous system, while dexmedetomidine is a highly selective alpha-2 adrenergic agonist providing profound sedation, muscle relaxation, and analgesia through central and peripheral receptor activation. When combined, these agents produce synergistic effects allowing reduced doses of each component while achieving reliable surgical anesthesia suitable for many small mammal procedures.

Ketamine was developed in the 1960s as a human anesthetic and rapidly found application in veterinary medicine due to its wide safety margin and ability to be administered via multiple routes. Dexmedetomidine represents the pharmacologically active enantiomer of medetomidine, providing equivalent effects at half the dose with potentially improved specificity. The combination of dissociative anesthetics with alpha-2 agonists evolved from earlier protocols using ketamine with xylazine, with medetomidine and dexmedetomidine offering superior potency and more predictable effects. This combination has become a cornerstone of small mammal anesthesia, particularly valuable when inhalant anesthesia equipment is unavailable or when injectable techniques offer advantages for specific patients or procedures.

Both components are available as injectable solutions that are combined at the time of administration. Ketamine is typically available at one hundred milligrams per milliliter concentration, while dexmedetomidine comes in various concentrations suitable for different patient sizes. The drugs can often be drawn into the same syringe for single-injection administration, simplifying delivery and reducing handling stress. The critical advantage of this combination is the ability to reverse the dexmedetomidine component using atipamezole, allowing partial reversal of the anesthetic effects and shortened recovery times, though the ketamine component cannot be reversed and must be metabolized or redistributed naturally.

The effectiveness of the ketamine-dexmedetomidine combination in small mammals is well-established through decades of clinical use across numerous species including ferrets, rabbits, guinea pigs, chinchillas, rats, mice, hamsters, and various exotic small mammals. The combination produces reliable immobilization with good muscle relaxation contributed by the alpha-2 component, unlike ketamine alone which causes muscle rigidity. The cardiovascular effects require understanding and monitoring, as alpha-2 agonists produce initial vasoconstriction with reflex bradycardia followed by potential hypotension. While ketamine is a controlled substance requiring DEA registration and careful record-keeping, its proven track record and the reversal option make this combination invaluable in exotic practice.

The primary uses of the ketamine-dexmedetomidine combination in small mammals include surgical anesthesia, procedural sedation and immobilization, and chemical restraint for diagnostic interventions requiring patient immobility. Surgical applications span the range of procedures performed in small mammals including spays, neuters, mass removals, dental extractions, abscess treatment, wound repairs, and emergency surgeries. The depth and duration of anesthesia achieved depends on doses administered, allowing the combination to serve purposes ranging from brief immobilization to extended surgical anesthesia. The ability to partially reverse the protocol at procedure completion provides flexibility in recovery management.

Species-specific applications of ketamine-dexmedetomidine encompass virtually all small mammals encountered in exotic practice. Ferrets commonly receive this combination for surgical procedures, with their larger size and reliable responses making the protocol straightforward to employ. Rabbits, despite their general sensitivity to anesthesia, have been successfully anesthetized with this combination, though careful dosing and monitoring remain essential. Guinea pigs and chinchillas can be immobilized for dental work, imaging, and surgical procedures. Rats and mice in both clinical and research settings are frequently anesthetized with ketamine-dexmedetomidine or ketamine-medetomidine protocols. Hamsters and gerbils can receive the combination with appropriate dose scaling for their small size.

Common conditions and procedures addressed using ketamine-dexmedetomidine anesthesia include diagnostic imaging requiring complete immobility such as radiography, computed tomography, and magnetic resonance imaging. Dental procedures including examination, extraction, and trimming of malocluded teeth are commonly performed under this protocol. Mass removal surgery addressing the unfortunately common tumors in small mammals utilizes this anesthesia combination. Wound management, abscess drainage, and foreign body removal benefit from the chemical restraint provided. Reproductive surgeries remain among the most frequent applications. Blood collection and other diagnostic sampling procedures can be accomplished humanely under ketamine-dexmedetomidine sedation.

Off-label applications include the use of lower doses for chemical restraint of fractious or aggressive patients to facilitate examination, sample collection, or minor procedures. The combination can be used to induce anesthesia for subsequent maintenance with inhalant agents when available, taking advantage of the rapid injectable induction while providing the controllability of inhalant maintenance. Emergency anesthesia when rapid immobilization is required uses the reliability of intramuscular injection that does not depend on establishing venous access. Wildlife rehabilitation facilities commonly use this combination for small mammal patients given its field applicability without sophisticated equipment requirements.

The ketamine-dexmedetomidine combination is often selected based on its unique advantages in specific clinical situations. When inhalant anesthesia equipment is unavailable, this combination provides reliable surgical anesthesia using only injectable medications. The partial reversibility with atipamezole offers recovery management options not available with many alternatives. The intramuscular administration route allows induction without prior venous access, valuable in fractious patients or very small animals. The controlled substance status of ketamine requires appropriate DEA registration and record-keeping but does not preclude its use. Cost considerations may favor this combination over newer alternatives like alfaxalone in some practice settings.

General dosing principles for ketamine-dexmedetomidine combinations in small mammals require individualization based on species, patient health status, desired anesthetic depth, procedure requirements, and anticipated duration, with all protocols designed and supervised by veterinarians experienced in exotic animal anesthesia. The ratio of ketamine to dexmedetomidine and total doses vary significantly between species and clinical goals. Lower doses produce sedation and chemical restraint while higher doses achieve surgical anesthesia. Debilitated patients require substantial dose reductions. Published protocols provide starting guidelines that should be adjusted based on individual patient response. Specific numeric doses are not provided here and must be determined by the attending exotic veterinarian based on current literature and patient assessment.

Route of administration options provide flexibility for different clinical situations. Intramuscular injection is most commonly employed, providing reliable absorption and straightforward administration without requiring venous access. Induction typically occurs within five to fifteen minutes depending on species and injection site. Subcutaneous administration results in slower, less predictable onset but may be used when intramuscular sites are limited. Intravenous administration produces the most rapid onset but requires pre-existing venous access and careful titration given the rapid effect onset. The combination is typically mixed in a single syringe for convenience, with most protocols combining the calculated volumes of each component for single-injection delivery.

Frequency and duration considerations depend on clinical requirements. For brief procedures, a single injection may provide adequate duration without supplementation. Longer procedures may require supplemental dosing, typically with additional ketamine alone since the dexmedetomidine's long duration usually maintains adequate sedation. Redosing the full combination increases recovery time since dexmedetomidine effects accumulate. If extended anesthesia is anticipated, the combination may be better suited for induction followed by inhalant maintenance. Recovery without reversal typically requires one to several hours depending on species and total doses, while atipamezole reversal significantly shortens recovery of the alpha-2 component.

Species-specific dosing considerations significantly influence protocol design. Ferrets generally respond predictably to ketamine-dexmedetomidine with published dose ranges available in exotic formularies. Rabbits require careful attention as they can be sensitive to both components, with some practitioners reducing dexmedetomidine doses to minimize cardiovascular effects. Guinea pigs have established protocols though individual variation occurs. Chinchillas are sensitive to hyperthermia under any anesthesia and may benefit from modified approaches. Rats and mice have been extensively studied in research settings with well-characterized pharmacokinetics. Hamsters, gerbils, and other small rodents require precise dose scaling for their tiny body sizes.

Compounding is not typically required as both medications are available in injectable formulations suitable for small mammal use. However, the small volumes required for very small patients may benefit from dilution of concentrated solutions to reduce measurement errors. A diluted working solution of dexmedetomidine may facilitate accurate dosing in tiny patients. When mixing the two drugs in one syringe, compatibility is generally acceptable for immediate use though prolonged storage of mixed solutions is not recommended. Precise measurement using appropriate syringes is critical, as small errors translate to significant dose variations in tiny patients.

Administration tips for ketamine-dexmedetomidine use include selecting appropriate intramuscular injection sites with adequate muscle mass, which may be challenging in very small patients. The quadriceps or epaxial muscles are commonly used. Ensuring the full calculated dose is delivered into muscle rather than subcutaneous tissue affects onset time and reliability. Animals should be left undisturbed following injection to allow smooth induction without stimulation. Pre-medication with opioids may be beneficial for painful procedures and can reduce total combination doses required. Atipamezole for reversal should be readily available and drawn up before the procedure so it can be administered promptly if needed.

Common side effects of ketamine-dexmedetomidine in small mammals include the expected pharmacologic effects of both components that require monitoring and management. The alpha-2 agonist produces initial peripheral vasoconstriction leading to reflex bradycardia, which can be profound and may require treatment with anticholinergics in some patients. Subsequent vasodilation and hypotension may occur, particularly as the alpha-2 effects peak. Respiratory depression occurs though is typically less severe than with some other anesthetic protocols. Hypothermia develops as with any anesthesia in small mammals and requires active warming. Ketamine maintains eye reflexes and may produce nystagmus, requiring eye lubrication during anesthesia.

Gastrointestinal effects following ketamine-dexmedetomidine anesthesia include the potential for decreased gut motility from both components. Alpha-2 agonists decrease gastrointestinal motility and secretions. Small mammals susceptible to gastrointestinal stasis including guinea pigs, chinchillas, and rabbits require careful monitoring for appetite return and normal fecal production following anesthesia. Extended recovery times without reversal increase the period of decreased gut function. Atipamezole reversal may help restore normal gastrointestinal motility more quickly by antagonizing the alpha-2 effects. Offering favored foods as recovery progresses and ensuring adequate hydration supports normal function return.

Species-specific adverse reactions to ketamine-dexmedetomidine have been observed across small mammal species. Ferrets generally tolerate the combination well but may show pronounced bradycardia. Rabbits can develop severe bradycardia and may benefit from anticholinergic premedication or lower dexmedetomidine doses. Guinea pigs may show prolonged recovery times. Chinchillas are sensitive to heat and require careful temperature management. Rats and mice generally respond appropriately though their small size makes precise monitoring challenging. Gerbils, which may be seizure-prone, warrant observation though ketamine-dexmedetomidine does not typically provoke seizures. Individual variation exists within all species.

Serious and rare side effects include severe bradycardia potentially progressing to cardiac arrest, particularly in sensitive species like rabbits without appropriate monitoring and intervention. Severe hypotension can compromise tissue perfusion, especially in debilitated patients. Respiratory depression can progress to respiratory arrest with excessive dosing. Emergence delirium can occur with ketamine, manifesting as vocalization and uncoordinated movements during recovery, which may be reduced by dexmedetomidine's concurrent sedation. Hyperthermia or hypothermia can develop depending on environmental temperature and patient thermoregulation. Prolonged recovery beyond expected duration may indicate overdose, underlying pathology, or hypothermia.

Owners should contact their veterinarian if their small mammal displays concerning signs following ketamine-dexmedetomidine anesthesia. Warning signs include failure to show appropriate recovery within the expected timeframe, especially if reversal was administered. Breathing difficulties including labored or irregular respirations warrant immediate attention. Extreme lethargy or failure to respond to gentle stimulation beyond expected recovery duration is concerning. Failure to resume eating and drinking within the appropriate timeframe for the species requires evaluation. Signs of distress, pain, or neurologic abnormalities should prompt veterinary contact. While some prolonged drowsiness is expected without reversal, owners should understand what normal recovery looks like for their species and procedure.

Species-specific contraindications to ketamine-dexmedetomidine are limited, though certain species present higher risk requiring careful protocol modification. Rabbits are notably sensitive to alpha-2 agonists and may develop severe bradycardia, though the combination can still be used with appropriate monitoring and intervention readiness. Animals with known hypersensitivity to either component should not receive the combination. Species with limited pharmacokinetic data require cautious extrapolation from better-studied species. The combination is generally avoided or used with extreme caution in animals known to be particularly sensitive to either dissociative anesthetics or alpha-2 agonists based on prior experience or breed predisposition.

Medical condition contraindications are significant for this combination due to the cardiovascular effects of both components. Significant cardiac disease, particularly bradyarrhythmias or conditions worsened by decreased cardiac output, represents a relative to absolute contraindication depending on severity. Severe respiratory disease increases risk given the respiratory depression potential. Hepatic dysfunction affects ketamine metabolism and may prolong recovery significantly. Renal disease affects excretion and may also extend duration of effect. Increased intracranial or intraocular pressure may be worsened by ketamine, making the combination inappropriate for patients with head trauma, glaucoma, or conditions involving elevated pressures. Shock, severe dehydration, or hypotension represent contraindications given the cardiovascular effects.

Age and reproductive considerations affect ketamine-dexmedetomidine use. Very young animals may have immature hepatic and renal function affecting drug clearance and recovery times. Geriatric patients often have subclinical cardiac, hepatic, or renal dysfunction that increases risk and may warrant alternative protocols or enhanced monitoring. Pregnancy is a relative contraindication as alpha-2 agonists can increase uterine tone potentially causing fetal distress, though the combination can be used when maternal health requires intervention with appropriate consideration. The combination can be used for cesarean section with attention to timing of reversal agent administration relative to delivery. Nursing mothers can receive the combination for necessary procedures with appropriate recovery before offspring contact.

Circumstances where ketamine-dexmedetomidine should be avoided or used with particular caution include facilities without appropriate monitoring capabilities, personnel not trained in recognizing and managing cardiovascular complications, and situations where emergency drugs and resuscitation equipment are not available. Animals with known seizure disorders represent a complex situation since ketamine can theoretically either provoke or suppress seizure activity. Patients who have recently received other medications with cardiovascular effects require careful evaluation. Elective procedures in patients with concerning pre-anesthetic findings should be postponed. The controlled substance status of ketamine requires appropriate DEA registration, secure storage, and accurate record-keeping that must be in place before use.

Medications requiring careful consideration with ketamine-dexmedetomidine include other central nervous system depressants that produce additive effects. Opioid analgesics are commonly added to this combination for painful procedures and produce synergistic sedation while allowing reduced doses of both primary components. Benzodiazepines like midazolam can be added to improve muscle relaxation and reduce ketamine-associated emergence effects. Other alpha-2 agonists should obviously not be combined with dexmedetomidine to avoid excessive alpha-2 receptor activation. Inhalant anesthetics used for maintenance following injectable induction produce additive cardiovascular and respiratory depression. All additions to the base protocol require thoughtful dose adjustments and enhanced monitoring.

Drug interactions affecting efficacy or producing safety concerns include anticholinergic agents like atropine or glycopyrrolate, which are sometimes administered to counteract alpha-2 induced bradycardia but may produce tachycardia if the bradycardia is primarily a reflex response to vasoconstriction rather than a direct cardiac effect. Catecholamines and other sympathomimetic drugs may produce exaggerated cardiovascular responses in the presence of alpha-2 agonists. Medications affecting hepatic enzymes could theoretically alter ketamine metabolism, though clinical significance is not well characterized. Concurrent administration of other drugs prolonging QT interval requires caution. The reversal agent atipamezole specifically antagonizes dexmedetomidine but has no effect on ketamine, so patients must still metabolize the dissociative component.

Interactions with dietary factors or supplements are generally minimal for this combination. Pre-anesthetic fasting recommendations vary by species and should be followed appropriately. Ferrets can be fasted briefly to reduce aspiration risk while rodents and rabbits generally should not be fasted due to their gastrointestinal physiology. Herbal supplements with sedative or cardiovascular effects could theoretically interact with the combination and should be documented during pre-anesthetic history taking. Patients receiving chronic medications affecting cardiovascular function require consideration of how these might interact with the combination's cardiovascular effects.

Safe and commonly used drug combinations build on the ketamine-dexmedetomidine base to create balanced anesthesia protocols. Opioid addition with buprenorphine, butorphanol, or hydromorphone provides analgesia and allows dose reduction of primary components. Benzodiazepine addition with midazolam improves muscle relaxation beyond what dexmedetomidine provides alone and may reduce emergence delirium. Anticholinergic premedication with atropine or glycopyrrolate may prevent or treat bradycardia, though routine use is debated. Local anesthetic techniques reduce systemic anesthetic requirements for appropriate procedures. When used for induction followed by inhalant maintenance, lower doses of the injectable combination can be used with anesthesia depth subsequently maintained with isoflurane or sevoflurane.

General precautions for ketamine-dexmedetomidine use in small mammals reflect both the inherent risks of anesthesia in these challenging patients and the specific effects of this drug combination. Small mammals face elevated anesthetic risk compared to domestic species due to limited physiologic reserves, rapid heat loss, high metabolic rates, and small body sizes complicating monitoring and intervention. The cardiovascular effects of alpha-2 agonists require particular attention, as bradycardia and blood pressure changes can compromise tissue perfusion in already small patients. Pre-anesthetic evaluation should identify patients at elevated cardiovascular risk who may benefit from alternative protocols or protocol modification.

Species-specific warnings for ketamine-dexmedetomidine address known sensitivities across small mammal species. Rabbits warrant particular attention due to their sensitivity to alpha-2 agonists and tendency toward severe bradycardia, with some practitioners recommending reduced dexmedetomidine doses or routine anticholinergic premedication in this species. Guinea pigs and chinchillas may show prolonged recovery requiring patient monitoring until full awakening. Small rodents require precise dosing where minor volume errors create significant dose variations. Ferrets generally tolerate the combination well but should be monitored for cardiovascular effects given the alpha-2 component. Hedgehogs may have underlying cardiac disease that affects response to this cardiovascular-active combination.

Monitoring requirements during ketamine-dexmedetomidine anesthesia must include cardiovascular assessment given the combination's effects on heart rate and blood pressure. Heart rate monitoring via stethoscope, Doppler, or electrocardiogram allows detection of significant bradycardia requiring intervention. Blood pressure monitoring provides valuable information about perfusion status when equipment is available for small patients. Respiratory rate and effort require continuous observation with ventilatory support readiness. Temperature monitoring is essential given hypothermia risk in small anesthetized mammals. Mucous membrane color and capillary refill time offer perfusion assessment. Pulse oximetry provides oxygenation data when appropriate probes are available.

Human safety considerations include the controlled substance status of ketamine requiring DEA registration, secure storage in locked containers, accurate usage records, and proper disposal of unused medication. Accidental self-injection of either component could produce significant effects requiring medical attention. Standard safe injection practices and sharps disposal protocols should be followed. Dexmedetomidine exposure through mucous membranes or broken skin can produce sedation and cardiovascular effects, warranting careful handling. Neither component poses particular environmental concerns with normal disposal, but controlled substance disposal must follow DEA requirements.

Management during anesthesia includes active warming using appropriate devices to prevent hypothermia. Patients should be positioned to optimize respiratory function. Eye lubrication is particularly important with ketamine since protective reflexes are maintained. Cardiovascular monitoring should continue throughout the procedure with intervention available for significant bradycardia. Recovery should occur in a quiet, warm environment. Atipamezole for dexmedetomidine reversal should be available with an appropriate dose calculated and drawn up. Reversal shortens recovery of alpha-2 effects but patients must still metabolize the ketamine component before full awakening.

Storage requirements for ketamine must comply with DEA regulations for Schedule III controlled substances, requiring secure storage in a locked cabinet or safe accessible only to authorized personnel with DEA registration. Ketamine should be stored at controlled room temperature protected from light and heat. Inventory records must be maintained documenting all acquisitions and usage with accurate accounting of quantities. Dexmedetomidine does not carry controlled substance requirements and should be stored at room temperature protected from light, with attention to manufacturer-specified storage conditions. Both medications should be kept in original containers with intact labeling until use. Expired or damaged medication requires proper disposal according to applicable regulations.

Shelf life and stability of both components follows manufacturer-assigned expiration dates when stored appropriately. Ketamine in sealed containers remains stable for extended periods at room temperature. Dexmedetomidine stability varies by specific product and should follow manufacturer guidelines. Once mixed together for administration, the combination should be used promptly rather than stored, as stability data for mixed solutions is limited. Any unused mixed solution should be disposed of appropriately rather than saved. Multi-dose vials of either component should be dated upon first puncture and used within manufacturer-specified timeframes. Visual inspection before use should confirm no color change, cloudiness, or particulate matter.

Safe handling and disposal of ketamine must comply with DEA requirements for controlled substances. Unused ketamine cannot simply be discarded but must be destroyed according to DEA-approved methods, which may include reverse distribution to authorized facilities or on-site destruction witnessed by two individuals with documentation. Dexmedetomidine disposal follows standard pharmaceutical waste protocols without controlled substance requirements. Used syringes and needles should be disposed of in sharps containers. Record-keeping for ketamine must account for every dose used, wasted, or destroyed. Facilities using ketamine must be prepared for periodic DEA inspection of storage, records, and inventory. The documentation burden associated with controlled substances is a significant consideration when selecting anesthetic protocols.

Hamsters, gerbils, mice, and rats present challenges for ketamine-dexmedetomidine use related to their tiny body sizes requiring precise measurement of very small medication volumes. Dilution of concentrated solutions may facilitate accurate dosing and reduce errors. Their extremely high metabolic rates result in relatively rapid drug clearance compared to larger species. Temperature support is critical as these small patients lose heat rapidly. Intramuscular injection sites are limited by minimal muscle mass. Rats and mice have been extensively studied with this combination in research settings, providing reliable pharmacokinetic data. Hamster and gerbil data is more limited but clinical experience supports appropriate use with careful dose scaling. Gerbils' seizure tendency does not typically contraindicate this combination but warrants monitoring.

Guinea pigs and chinchillas can be anesthetized with ketamine-dexmedetomidine with attention to their species-specific characteristics. Guinea pigs may show variable responses requiring careful observation and potentially supplemental dosing for some individuals while others achieve adequate depth with standard protocols. Their susceptibility to respiratory issues under anesthesia warrants monitoring. Guinea pigs cannot synthesize vitamin C, and stressed animals may have depleted stores affecting physiologic resilience. Chinchillas are notably sensitive to heat stress, making careful temperature management essential to prevent hyperthermia while still preventing hypothermia during anesthesia. Both species require monitoring for normal appetite return given their susceptibility to gastrointestinal stasis.

Ferrets generally respond well to ketamine-dexmedetomidine with predictable dose-response relationships and straightforward protocol implementation. Their larger size among small mammals allows more precise dosing and easier monitoring. Venous access for potential supportive care is more feasible than in tiny rodents. Ferrets commonly have underlying disease including insulinoma, adrenal disease, and cardiac conditions that should be considered in protocol planning. Pre-anesthetic blood glucose testing is advisable given insulinoma prevalence, as both hypoglycemia and the stress of procedures can affect these patients. The ability to reverse the dexmedetomidine component is valuable for minimizing prolonged recovery that could stress insulinoma patients.

Hedgehogs, sugar gliders, and other exotic small mammals each present unique considerations for ketamine-dexmedetomidine anesthesia. Hedgehogs commonly have subclinical cardiac or respiratory disease that may affect response to this cardiovascular-active combination. Their defensive curling complicates injection delivery. Sugar gliders are very small and stress-sensitive, requiring precise dosing and careful monitoring. Their tendency toward self-mutilation when stressed makes appropriate anesthetic depth important. Other exotic small mammals including prairie dogs, degus, and various pocket pets may be encountered with limited species-specific pharmacologic data, requiring cautious extrapolation from better-studied species and consultation with exotic animal specialists for protocol recommendations.

Same-class alternatives using ketamine with different alpha-2 agonists include the ketamine-medetomidine combination, which is pharmacologically very similar since medetomidine contains both dexmedetomidine and its inactive enantiomer, requiring twice the dose for equivalent effect. Ketamine-xylazine was the historical standard before medetomidine and dexmedetomidine became available, with xylazine being less potent and having a different side effect profile. Ketamine-detomidine represents another alpha-2 option used more commonly in equine practice. All ketamine-alpha-2 combinations share the advantage of alpha-2 reversibility with appropriate antagonists, though the specific antagonist varies with the agonist used. The choice among alpha-2 agonists typically reflects availability, familiarity, and patient factors.

Different-class alternatives for injectable anesthesia include alfaxalone, either alone or combined with midazolam, which provides reliable anesthesia without controlled substance requirements but without the alpha-2 reversal option. Propofol offers rapid onset and short duration suitable for brief procedures in patients with venous access. Tiletamine-zolazepam combines a dissociative with a benzodiazepine but cannot be reversed and has prolonged recovery in some species. Inhalant anesthesia with isoflurane or sevoflurane provides alternatives when equipment is available, offering superior controllability and rapid recovery. The selection among alternatives depends on procedure requirements, patient factors, available equipment, regulatory considerations, and practitioner expertise.

Combination therapy options building on ketamine-dexmedetomidine optimize anesthesia outcomes through multimodal approaches. Adding opioid analgesics provides pain control while reducing required doses of both primary components. Benzodiazepine addition with midazolam improves muscle relaxation and may reduce emergence effects. When used for induction followed by inhalant maintenance, the combination provides reliable injectable induction without requiring venous access while inhalants provide controllable maintenance. Local and regional anesthesia techniques reduce systemic anesthetic requirements for appropriate procedures. The reversal agent atipamezole is an essential component of this protocol, allowing shortened recovery when appropriate while understanding that ketamine effects must still resolve naturally. Post-operative analgesics address pain beyond the anesthetic period since neither ketamine nor alpha-2 agonists provide extended pain control.